Outcomes of Nonsuspicious Contralateral Nodules with Active Surveillance After Lobectomy in Patients with Papillary Thyroid Carcinoma

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Aug 1

PMID 35909520

Authors

Hui Huang

Jie Liu

Xiaolei Wang

Shaoyan Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To observe the outcomes of nonsuspicious contralateral nodules with active surveillance in patients with papillary thyroid carcinoma (PTC).

Methods: 4pt?>Consecutive patients who underwent lobectomy for PTC were retrospectively reviewed. Patients with one or more nodules with nonsuspicious ultrasonography (US) features in the contralateral lobe were included.

Results: Two hundred and eighty-three patients were included. All patients underwent thyroid lobectomy with ipsilateral prophylactic central neck dissection. A total of 123 patients (43.5%) were classified as ATA low-risk, and 160 patients (56.5%) were classified as intermediate-risk. The median size of the contralateral nodules was 3 mm (range, 2 to 16 mm). After a period of follow-up, the median size change of contralateral nodules was 0 mm (range, -7 to 8 mm). Eight patients (2.8%) had nodule growth >3 mm, 223 patients (78.8%) had stable or decreased nodules, and 52 patients (18.4%) had no detectable nodules. Nodules in 24 patients had suspicious US features, 16 of which were diagnosed with PTMC by either cytology after FNA (in 7 patients) or histopathology after completion thyroidectomy (in 9 patients). Another four patients received completion thyroidectomy for ipsilateral cervical lymph node metastasis. The 5-year residual lobe recurrence (RLR) rate and recurrence-free survival (RFS) rate were 7.4% and 89.8%, respectively. Multivariate analysis showed that multifocality and ATA intermediate-risk were independent predictors for RLR (HR4.083, 95%CI 1.480-11.261, = 0.007; HR 6.045, 95%CI 1.370-26.662, = 0.017, respectively) and RFS (HR 5.240, 95%CI 2.114-12.991, < 0.001; HR 5.223, 95%CI 1.353-17.765, = 0.008, respectively).

Conclusions: Active surveillance for nonsuspicious contralateral nodules in patients with low-risk and selected intermediate-risk PTC is safe. Multifocality and ATA intermediate-risk are predicters for recurrence. Early detection and salvage surgery are effective.

Citing Articles

Predicting Extrathyroidal Extension in Papillary Thyroid Carcinoma Using a Clinical-Radiomics Nomogram Based on B-Mode and Contrast-Enhanced Ultrasound.

Jiang L, Guo S, Zhao Y, Cheng Z, Zhong X, Zhou P Diagnostics (Basel). 2023; 13(10).

PMID: 37238217 PMC: 10217699. DOI: 10.3390/diagnostics13101734.

References

Ma T, Wang H, Liu J, Zou J, Liu S . Should Contralateral Nodules Be an Indication of Total or Completion Thyroidectomy for Patients With Unilateral Papillary Thyroid Carcinoma?. Front Endocrinol (Lausanne). 2021; 12:723631. PMC: 8380921. DOI: 10.3389/fendo.2021.723631. View

Kuba S, Yamanouchi K, Hayashida N, Maeda S, Adachi T, Sakimura C . Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study. Int J Surg. 2016; 38:143-148. DOI: 10.1016/j.ijsu.2016.09.083. View

Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A . The natural history of benign thyroid nodules. JAMA. 2015; 313(9):926-35. DOI: 10.1001/jama.2015.0956. View

Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H . Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2013; 38(1):68-79. DOI: 10.1007/s00268-013-2224-1. View

Iacobone M, Jansson S, Barczynski M, Goretzki P . Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2013; 399(2):141-54. DOI: 10.1007/s00423-013-1145-7. View

Davies L, Welch H . Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014; 140(4):317-22. DOI: 10.1001/jamaoto.2014.1. View

Harries V, Wang L, McGill M, Xu B, Tuttle R, Wong R . Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?. Surgery. 2019; 167(1):10-17. PMC: 6904525. DOI: 10.1016/j.surg.2019.03.031. View

Frates M, Benson C, Doubilet P, Kunreuther E, Contreras M, Cibas E . Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006; 91(9):3411-7. DOI: 10.1210/jc.2006-0690. View

Park J, Lee H, Jang H, Kim H, Yi J, Lee W . A proposal for a thyroid imaging reporting and data system for ultrasound features of thyroid carcinoma. Thyroid. 2009; 19(11):1257-64. DOI: 10.1089/thy.2008.0021. View

10.

Kuo S, Lin S, Chao T, Hsueh C, Lin K, Lin J . Prognosis of multifocal papillary thyroid carcinoma. Int J Endocrinol. 2014; 2013:809382. PMC: 3892555. DOI: 10.1155/2013/809382. View

11.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

12.

Al Afif A, Williams B, Rigby M, Bullock M, Taylor S, Trites J . Multifocal Papillary Thyroid Cancer Increases the Risk of Central Lymph Node Metastasis. Thyroid. 2015; 25(9):1008-12. DOI: 10.1089/thy.2015.0130. View

13.

Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K . An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003; 13(4):381-7. DOI: 10.1089/105072503321669875. View

14.

Hauch A, Al-Qurayshi Z, Randolph G, Kandil E . Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014; 21(12):3844-52. DOI: 10.1245/s10434-014-3846-8. View

15.

Vaisman F, Shaha A, Fish S, Tuttle R . Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011; 75(1):112-9. DOI: 10.1111/j.1365-2265.2011.04002.x. View

16.

Pacini F, Elisei R, Capezzone M, Miccoli P, Molinaro E, Basolo F . Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid. 2001; 11(9):877-81. DOI: 10.1089/105072501316973145. View

17.

Lee J, Park J, Lee C, Chung W, Park C . Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid. 2013; 23(11):1408-15. DOI: 10.1089/thy.2012.0463. View

18.

Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G . Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?. J Clin Endocrinol Metab. 2012; 97(8):2748-53. DOI: 10.1210/jc.2012-1123. View

19.

Zhao Q, Ming J, Liu C, Shi L, Xu X, Nie X . Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol. 2012; 20(3):746-52. DOI: 10.1245/s10434-012-2654-2. View

20.

Brito J, Al Nofal A, Montori V, Hay I, Morris J . The Impact of Subclinical Disease and Mechanism of Detection on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Olmsted County, Minnesota During 1935 Through 2012. Thyroid. 2015; 25(9):999-1007. PMC: 4560845. DOI: 10.1089/thy.2014.0594. View